Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (143 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: pulmonarypressurearterialvascularhypertension
  Phrases that lowered it: patientsinvestigate theto investigateinhaledconcomitant
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 41.9% (raises risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Design: single group (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 95.7% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 80 (lowers risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 5 (raises risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH NCT02725372 · started 2016 · scored riskier than 97% of active trials terminated
• 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF NCT02267655 · started 2015 · scored riskier than 50% of active trials completed
• Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide NCT01092559 · started 2010 · scored riskier than 85% of active trials completed
• Effect of Inhaled Albuterol in Pulmonary Hypertension NCT03270332 · started 2017 · scored riskier than 29% of active trials completed
• Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism NCT00848731 · started 2009 · scored riskier than 92% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.